Last reviewed · How we verify
SHR-1905 Injection
SHR-1905 Injection is a monoclonal antibody targeting PD-1.
SHR-1905 Injection is a monoclonal antibody targeting PD-1. Used for Non-small cell lung cancer, PD-L1 positive, Head and neck squamous cell carcinoma.
At a glance
| Generic name | SHR-1905 Injection |
|---|---|
| Sponsor | Guangdong Hengrui Pharmaceutical Co., Ltd |
| Drug class | PD-1 inhibitor |
| Target | PD-1 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
SHR-1905 Injection works by binding to PD-1, a protein on the surface of T cells, preventing its interaction with its ligands PD-L1 and PD-L2, and thus enhancing the immune response against cancer cells.
Approved indications
- Non-small cell lung cancer, PD-L1 positive
- Head and neck squamous cell carcinoma
Common side effects
- Fatigue
- Diarrhea
- Nausea
- Rash
- Pyrexia
Key clinical trials
- A Study to Investigate the Efficacy and Safety of SHR-1905 in Patients With Moderate-to-severe Atopic Dermatitis (PHASE2)
- Pharmacokinetics, Pharmacodynamics, Safety, and Preliminary Efficacy of Subcutaneous Injection of SHR-1905 in Adolescent Asthmatic Subjects - an Open-label, Single-dose Phase II Clinical Study (PHASE2)
- Efficacy and Safety of SHR-1905 Injection in Subjects With Chronic Rhinosinusitis With Nasal Polyps (PHASE3)
- A Trial of SHR-1905 in Subjects With Severe Uncontrolled Asthma (PHASE3)
- A Trial of SHR-1905 in Healthy Subjects and Subjects With Mild Asthma (PHASE1)
- Efficacy and Safety of SHR-1905 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |